Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Europe Drug Review Regulation

Potential Blockbuster Lebrikizumab Among Latest Drugs Up For Decision On EU Approval

  • News

Executive Summary

The European Medicines Agency  is set to decide whether to back EU marketing approval for eight new drugs.

You may also be interested in...



Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna

The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs. 

Approval of Daiichi Sankyo’s Vanflyta Sets Up FLT3 Head-To-Head Competition

After over a decade in development, Vanflyta scored FDA approval in newly diagnosed FLT3-ITD acute myeloid leukemia, where Novartis FLT3 inhibitor Rydapt has been on the market for years.

Keeping Track: Tumor-Agnostic Approval For Novartis; Submissions From Krystal, Menarini, And Astellas

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Europe Drug Review Regulation
Latest Headlines

Europe’s Proposed Chemical Ban Could Hit Many Thousands Of Global Marketing Authorizations

EU Advances Plans For New Catalogs Of RWD Sources & Non-Interventional Studies

Orchard On The Trials, Tribulations And Triumphs Of Gene Therapy HTA

BrainStorm’s NurOwn Gets Many, Many Thumbs Down From US FDA Panel

See All
UsernamePublicRestriction

Register

PS148839

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By